Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors

Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors

The non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone (FIN) improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) in type 2 diabetes (T2D). We explored the effect of FIN in a novel model of type 1 diabetic Munich Wistar Frömter (MWF) rat (D) ind...

Full description

Bibliographic Details
Main Authors: M. Sanz-Gómez, F.J. Manzano-Lista, E. Vega-Martín, D. González-Moreno, M. Alcalá, M. Gil-Ortega, B. Somoza, C. Pizzamiglio, L.M. Ruilope, I. Aránguez, P. Kolkhof, R. Kreutz, M.S. Fernández-Alfonso
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Chronic kidney disease
Type 1 diabetes
Streptozotocin
Finerenone
Bone morphogenetic proteins
Perivascular adipose tissue
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223014592

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223014592

Similar Items